Trial by Dutch laboratories for evaluation of non-invasive prenatal testing. Part I—clinical impact by Oepkes, D. et al.
ORIGINAL ARTICLE
Trial by Dutch laboratories for evaluation of non-invasive prenatal
testing. Part I—clinical impact
Dick Oepkes1, G. C. (Lieve) Page-Christiaens2, Caroline J. Bax3, Mireille N. Bekker2,4, Catia M. Bilardo5, Elles M. J. Boon6,
G. Heleen Schuring-Blom7, Audrey B. C. Coumans8, Brigitte H. Faas9, Robert-Jan H. Galjaard10, Attie T. Go11, Lidewij Henneman12,
Merryn V. E. Macville13, Eva Pajkrt14, Ron F. Suijkerbuijk15, Karin Huijsdens-van Amsterdam16, Diane Van Opstal10, E. J. (Joanne) Verweij1,
Marjan M. Weiss12, Erik A. Sistermans12*and for the Dutch NIPT Consortium
1Department of Obstetrics, Leiden University Medical Center, Leiden, The Netherlands
2Department of Obstetrics and Gynaecology, University Medical Center Utrecht, Utrecht, The Netherlands
3Department of Obstetrics and Gynaecology, VU University Medical Center, Amsterdam, The Netherlands
4Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands
5Department of Obstetrics and Gynaecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
6Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
7Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
8Department of Obstetrics and Gynaecology, Maastricht UMC+, Maastricht, The Netherlands
9Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
10Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
11Department of Obstetrics and Gynecology, Erasmus Medical Center, Rotterdam, The Netherlands
12Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands
13Department of Clinical Genetics, Maastricht UMC+, Maastricht, The Netherlands
14Department of Obstetrics and Gynaecology, Academic Medical Centre, Amsterdam, The Netherlands
15Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
16Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands
*Correspondence to: Erik A. Sistermans. E-mail: e.sistermans@vumc.nl
ABSTRACT
Objective To evaluate the clinical impact of nationwide implementation of genome-wide non-invasive prenatal
testing (NIPT) in pregnancies at increased risk for fetal trisomies 21, 18 and 13 (TRIDENT study).
Method Women with elevated risk based on ﬁrst trimester combined testing (FCT ≥ 1:200) or medical history, not
advanced maternal age alone, were offered NIPT as contingent screening test, performed by Dutch University Medical
laboratories. We analyzed uptake, test performance, redraw/failure rate, turn-around time and pregnancy outcome.
Results Between 1 April and 1 September 2014, 1413/23 232 (6%) women received a high-risk FCT result. Of these, 1211
(85.7%) chose NIPT. One hundred seventy-nine women had NIPT based on medical history. In total, 1386/1390
(99.7%) women received a result, 6 (0.4%) after redraw. Mean turn-around time was 14 days. Follow-up was available
in 1376 (99.0%) pregnancies. NIPT correctly predicted 37/38 (97.4%) trisomies 21, 18 or 13 (29/30, 4/4 and 4/4
respectively); 5/1376 (0.4%) cases proved to be false positives: trisomies 21 (n = 2), 18 (n = 1) and 13 (n = 2). Estimated
reduction in invasive testing was 62%.
Conclusion Introduction of NIPT in the Dutch National healthcare-funded Prenatal Screening Program resulted in
high uptake and a vast reduction of invasive testing. Our study supports offering NIPT to pregnant women at
increased risk for fetal trisomy. © 2016 The Authors. Prenatal Diagnosis published by John Wiley & Sons, Ltd.
Funding sources: Supported by a grant from The Netherlands Organisation for Health Research and Development (ZonMw, No. 200340002)
Conﬂicts of interest: Dr. Oepkes and Verweij have previously participated in clinical research sponsored by Ariosa Diagnostics and Natera Inc. Dr. Page-Christiaens
is employed as an Associated Medical Director at Illumina Inc. since January 18, 2016.
INTRODUCTION
Non-invasive prenatal testing (NIPT) for fetal trisomy using
cell-free DNA analysis from maternal plasma is increasingly
offered to pregnant women worldwide, reducing the
number of invasive diagnostic tests.1 Of the women eligible
for invasive testing by maternal age and ﬁrst trimester
combined test (FCT), more than 90% carry a healthy child.
Fear for invasive testing makes many of these women
refrain from further testing,2–4 and some even refrain from
screening.5,6
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In March 2011, a multidisciplinary Dutch NIPT Consortium
was founded as a platform for collaboration between obstetric
caregivers, clinical geneticists and laboratory specialists, the
national prenatal screening organization, the Dutch Genetic
Alliance (VSOP), ethicists, insurance companies and policy
makers. In an increasing number of countries, NIPT has been
introduced commercially without governmental guidance. In
the Netherlands such an introduction is subject to a
governmental license under the Population Screening Act
because screening is offered for untreatable disorders. The
NIPT Consortium received this license as well as funding for
the nationwide TRIDENT study (Trial by Dutch laboratories
for Evaluation of Non-Invasive Prenatal Testing), starting 1
April 2014. The license approved NIPT as an alternative option
to invasive testing for women with a ≥1:200 FCT result and for
women with an increased risk for trisomy 21, 18 or 13 because
of medical history. Direct access to NIPT based on maternal
age alone was not allowed, and the direct access to invasive
testing based on maternal age alone was halted.
The TRIDENT license was initially granted for two years. We
expected to perform 1000–2000 NIPTs in the ﬁrst year. The aim
of this study was to evaluate uptake, test results, test
performance and pregnancy outcomes of all pregnancies after
the ﬁrst 1000 participating women had delivered. Parallel to
this study, we performed a questionnaire study to analyze
women’s preferences and decision-making. Results are
reported separately (Van Schendel et al.7 Paper Part II).
METHODS
Organization of prenatal screening in the Netherlands
In the Netherlands, FCT has been available for all pregnant
women since 2007, upon payment of €165. Uptake is between
25 and 30%.8 All follow-up testing including NIPT is currently
reimbursed by the compulsory health insurance after
subtraction of a deductible of 360 euros. National screening
programs are coordinated and monitored by the Centre for
Population Screening of the National Institute for Public
Health and the Environment (RIVM/CvB), which resorts under
the Ministry of Health, Welfare and Sport. This organization
provides uniform patient information in different languages,
guidance documents and e-learning for professionals.
Participating women and inclusion procedure
Our study group consisted of all pregnant women who chose
NIPT because of an increased risk for trisomy 21, 18 or 13
based on FCT result or based on medical history (previous
child with such a trisomy or a balanced translocation in one
of the parents). FCT results were reported as risks for
trisomy 21, 18 and 13. FCT is monitored and audited per
region and reported to the RIVM/CvB. A program committee
(with representatives of the participating professions and
organizations) advises the CvB about the program. Eight
Regional Centers (afﬁliated to the University Medical Centers)
have been licensed for the FCT screening and are monitoring
and auditing the quality of Nuchal Translucency (NT)
measurements as well as the biochemical part of the testing
as the ﬁnal metrics of the FCT. FCT includes measurement of
PAPP-A (Pregnancy-Associated Plasma Protein A) and fß-hCG
(beta subunit of human Chorionic Gonadotrophin). NT
measurements are performed by trained ultrasonographists
according to guidelines and with requirements for a minimal
number of measurements annually. Exclusion criteria for the
study were: multiple pregnancies, vanishing twins, fetal nuchal
translucency ≥3.5mm or other structural anomalies,
chromosome anomaly or history of maternal malignancy,
gestational age <10 + 0weeks, women <18 years old and
inability to give informed consent.
As required in the National Prenatal Screening Protocol, all
pregnant women were asked whether they wanted to be
informed on options for screening for fetal anomalies at the
ﬁrst prenatal care visit. If so, they were counseled by a
certiﬁed midwife or obstetrician on the FCT and the 20-week
anomaly scan, and about NIPT as an alternative for invasive
testing. As part of the TRIDENT study, counselors had
received additional training on relevant aspects of NIPT.
Written information and a website (www.meerovernipt.nl)
were available for further reading.
Women with an increased risk based on FCT or medical
history were referred for further counseling to one of the
eight Centers for Prenatal Diagnosis, or one of their satellite
centers. Women were given the choice between NIPT,
invasive testing or no (follow-up) test. Extensive oral and
written information on all tests was provided. For counseling
on NIPT, performance data from a review by Mersy et al.9
were used: sensitivity and speciﬁcity around 99.0% for
trisomy 21. We predicted a turn-around time (TAT) of 14–
21 days. Women were informed that NIPT examines DNA
fragments from the placenta cells rather than from the fetus
itself, providing a biological explanation for some false
positive and very rare false negative results. The study was
a nationwide research study on all aspects of introducing
NIPT in the prenatal screening program for trisomy 21, 13
and 18. A genome-wide approach was used allowing the
detection of other chromosomal abnormalities. Women
were informed that other abnormal results besides
trisomy 21, 18 or 13 are occasionally found, and that any
potentially clinically relevant abnormal NIPT result would
be discussed with them, potentially leading to an offer of
detailed ultrasound, invasive testing and/or parental
testing. Women were informed that fetal sex and sex
chromosomal aneuploidies would not be communicated,
as the ministerial license did not allow analysis of sex
chromosomes.
For counseling on invasive testing the following
information was given: how the procedures are performed,
risk-ﬁgures for procedure-related miscarriage (0.3–0.5%),
TAT and genetic tests done by chorionic villi sampling
(CVS) or amniocentesis (AS). The latter differed according
to the indication and patient history and local policy and
could be QF-PCR for trisomy 13, 18 and 21 only, karyotyping
or array.
All women signed an informed consent form. Permission
for the study was granted by the Minister of Health (350010-
118701-PG). The study was also approved by local University
Medical Center Ethics Committees.
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Sample collection
All eight University Hospitals and 13 satellite centers
participated. Women were given a unique TRIDENT study
number. A custom-made TRIDENT page was integrated in
the Astraia fetal medicine database (version 1.23, astraia
software GmbH, Munich, Germany) and contained ﬁelds for
entry of maternal characteristics, FCT results, invasive prenatal
diagnosis and pregnancy outcome data.
Two to four EDTA anticoagulated or Cell-Free DNA BCT
(Streck, Omaha NE, USA) tubes of 6 to 10-ml blood were taken
and transported the same day (EDTA tubes) or within 7 days
(Streck tubes) to a Clinical Genetics laboratory for analyses.
The laboratories kept a dataset for cross-checking. The RIVM/
CvB database Peridos, to which data on prenatal screening
are uploaded from the electronic patient ﬁles of obstetric
caregivers, was used to calculate uptake of NIPT in the group
of women with an increased risk based on the FCT.
Massively parallel shotgun sequencing
In the years preceding the TRIDENT study, all eight University
Hospital Genetic Laboratories had validated massively parallel
shotgun sequencing for the prediction of fetal trisomies, and
shared validation samples for quality control. During the
project, six laboratories performed the testing, and all were
involved in analysis, interpretation and reporting. Genome-
wide sequencing was performed with the Illumina HiSeq
2500 or the Life Technologies 5500 W SOLiD sequencer.
Bioinformatic analysis was performed either by z-score
calculation, with z-scores above 3.0 as a cut-off value between
indicative or not indicative for trisomy, or by the
WISECONDOR algorithm under standard settings to call
trisomies.10 As an extra check, several labs combined the two
methods. WISECONDOR detects trisomies and monosomies
of all autosomes, as well as deletions and duplications
>20Mb. Fetal fraction was not routinely measured. One
laboratory estimated fetal fraction in male fetuses and
requested a redraw when fetal fraction was lower than 4%.
Outcome variables
The primary clinical outcome data for this part of the TRIDENT
study were uptake, deﬁned as the percentage of women
eligible for NIPT based on FCT result that actually chose to
have NIPT, test characteristics of NIPT performed by the Dutch
laboratories, failure rate and TAT (days between blood draw
and reporting to the patient). As a secondary outcome, we
made an inventory of abnormal ﬁndings other than full
trisomy 21, 18 and 13 and their outcome. The standard
follow-up procedure was a return form ﬁlled out and returned
by the woman after pregnancy/birth. In case of abnormal
ﬁndings, follow-up data were gathered as needed: invasive
testing results, ultrasound data, genetic testing in products of
conception (cord blood, placenta), birth data and data of
postnatal examination.
Statistical analysis
Descriptive statistics, with mean, SD and range, were used
to describe uptake, failure rate and TAT. Predictive
performance was analyzed using two-by-two tables, and
calculation of sensitivity, speciﬁcity, and positive and
negative predictive values.
RESULTS
Five months into the TRIDENT study, we already had included
over 1000 pregnancies. We decided to report on the results
between the start of the study 1 April 2014 and 1 September
2014, as soon as clinical follow-up was complete. The last
woman of this group delivered in March 2015. Characteristics
of the study group are given in Table 1.
During the ﬁrst ﬁve months of the study, 1413/23 232 women
(6.1%) who underwent FCT received a trisomy risk ≥1:200. Of
these, 1211 underwent NIPT; uptake in the screening group
was 1211/1413 (85.7%). An additional 179 NIPT tests were done
because of medical history. The uptake in this subgroup could
not reliably be assessed because of an unknown denominator.
In total, 1390 (1211 + 179) pregnant women had a blood sample
taken.
A result was issued after a single blood draw in 1380/1390
(99.3%) cases. Of the 10 remaining cases, one woman elected
to directly undergo amniocentesis, showing a normal
karyotype. In the other nine cases, a redraw was done and
three samples failed again (overall failure rate 0.3% (4/1390)).
The failures were because of fetal fractions <4% (n = 3), or the
results of the WISECONDOR algorithm being inconclusive,
most likely because of bad DNA quality (n = 1). One woman
was morbidly obese (BMI 52); the other three had a normal
weight/BMI. Four children without anomalies were born.
Results were issued after a mean of 14 days (range 5–32); 95%
of results were available within 21 days. TAT improved in later
phases of the study because of faster equipment.
Table 1 Characteristics of 1390 pregnant women at increased
risk for fetal trisomy who underwent NIPT
Characteristics n (%)
Maternal age (y)
<36 603 (43)
≥36 703 (51)
Unknown 84 (6)
Parity
0 300 (22)
1 or more 486 (35)
Unknown 604 (43)
Indication for NIPT
FCT risk ≥ 1:200 1211 (87)
Medical history 179 (13)
FCT risk for fetal trisomy
≥1:10 48 (3)
1:11 – 1:50 239 (17)
1:51 – 1:100 282 (20)
1:101 – 1:200 482 (35)
Unknown 160 (25)
FCT, ﬁrst trimester combined test.
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Accuracy
Of the 1386 successful NIPT samples, 1325 (95.6%) were
reported as normal and 42 (3.0%) as either trisomy 21
(n = 31), 18 (n = 5) or 13 (n = 6). Of these 42 cases, a full trisomy
was conﬁrmed in the fetus in 34 cases, by invasive testing
(n = 33) or karyotyping of postnatal tissues (n = 1) (Table 2);
19/1386 cases had an abnormal result involving other trisomies
or subchromosomal aberrations (see following paragraph for
details). Five false positive cases were found (0.4%, n = 2
trisomy 21, n = 1 trisomy 18 and n = 2 trisomy 13). In two
pregnancies, NIPT showed unclear results, which were
reported as very unlikely to be full T21 but mosaic could not
be ruled out. In both cases, the parents opted for
amniocentesis which revealed a normal karyotype; both
children are alive and well. As these two events were not
reported as T21, they are included in the ‘normal result’ group
for this paper. No pregnancies with an abnormal NIPT result
were terminated without conﬁrmation by invasive testing.
We report one false negative case: trisomy 21 (46,XX,i(21)
(q10)) was detected in amniotic ﬂuid after invasive testing
because of ultrasound anomalies at routine scanning. The
parents chose to continue the pregnancy. Analysis of the
placenta after birth showed absence of this isochromosome
from the cytotrophoblast layer, whereas it was present as a
mosaic (66%) in the mesenchyme layer.
Details of the discordant NIPT results are given in Table 3.
Two-by-two tables and test characteristics are given in
Tables 4, 5 and 6 for each of the three trisomies.
Additional ﬁndings
In 19/1386 (1.4%) cases, which is 31% of all abnormal cases,
other full trisomies (1.1%, n = 15) (T22 n = 1, T20 +T2 n = 1,
T16 n = 6, T9 n = 1, T8 n = 2, T7 n = 4) or subchromosomal
aberrations (0.3%, n = 4) (deletions n = 3 (11p, 12q, 18p),
duplications n = 1 (7q)) were reported (Table 2). As 1076/1386
cases underwent genome-wide analysis by WISECONDOR,
the frequency of additional ﬁndings is actually somewhat
higher (1.7%). No sex chromosomal aneuploidies were found
as the license did not allow analysis of sex chromosomes. All
cases were counseled by the clinical geneticist on possible
consequences and options for further testing. In two cases,
the pregnancy was terminated after conﬁrmation by invasive
testing (12q and 18p deletion, both without clear ultrasound
abnormalities). The 11p deletion was conﬁrmed to originate
from the healthy mother. In two of the 17 ongoing pregnancies,
a child with multiple structural anomalies was born, one case
of T16 NIPT result but normal genotype (array) in the child,
and one case of T9 NIPT result which was mosaic in the child.
In both cases, parents refrained from invasive testing. In 10
Table 2 Outcome of NIPT in pregnancies at increased risk for trisomy 21, 18 or 13
NIPT result All Invasive tests (abnormal genotype) TOP IUFD Live-born (abnormal genotype)
Normal 1311 21 (5) 8a 16 1287 (2b)
Trisomy 21 31 29 (27) 25 2 4 (2)
Trisomy 18 5 5 (4) 3 1 1 (0)
Trisomy 13 6 3 (2) 2 2 2 (0)
Other trisomies 15 9 (1) 0 0 15 (2)
Subchromosomal abnormalities 4 3 (2) 2 0 2 (0)
Failed 4 1 (0) 0 0 4 (0)
Data are n. Data from 1376 pregnancies with complete outcome data.
TOP, termination of pregnancy; IUFD, intrauterine fetal demise.
aOne for triploidy, seven for ultrasound anomalies.
bOne trisomy 21, one 22q11.2 del.
Table 3 Outcome of pregnancies with false positive and false negative NIPT results
NIPT MA (y) BMI GA (wk) FCT risk z-Score Ultrasound Invasive test Child phenotype Cord blood
T21 41 26 12 + 3 1:147 (T21) 4.96 Nl Amnio QF-PCR
and FISH normal
Nl female
T21 29 22 13 + 5 1:80 (T21) 3.29 Nl None Nl female
T18 39 29 15 + 0 1:85 (T18) 4.40 Nl Amnio QF-PCR and
karyotype normal
Nl female
T13 39 22 15 + 4 1:5000 (T13)
1:35 (T21)
5.11 Nl None Nl male QF-PCR normal
T13 37 22 13 + 5 1:6134 (T13)
1:121 (T21)
4.4 Nl None Nl male Karyotype normal
Nl 34 23 13 + 5 1:140 (T21) <3 Markers for T21 Amnio T21, 46,XX,i(21)(q10) Live-born Down
syndrome female
MA, maternal age; BMI, body mass index; GA, gestational age; FCT, ﬁrst trimester combined test; Nl, normal.
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additional children, a growth-restricted infant was born. A
detailed report of an extended cohort with additional ﬁndings,
including follow-up testing, clinical relevance and pregnancy
outcomes will be published separately.
Outcome
Complete follow-up of pregnancy outcomes was obtained for
1376/1390 (99.0%) pregnancies. Three children died in the
neonatal period, two related to severe prematurity without
evidence of structural or chromosomal anomalies, and one
because of severe cardiac malformations (all three normal
arrays). One live-born child was found to have a 22q11.2
deletion, associated with diGeorge syndrome (too small to
detect with the method used). Its heart defect was not detected
during pregnancy. Three women with a prenatal diagnosis of
trisomy 21 elected to continue the pregnancy; all three
children were born alive. No other live-born child was reported
to have chromosomal abnormalities.
Invasive testing
Fifty-three invasive tests were done following NIPT results
(5 CVS, 46 AS, 1 CVS and AS): 37 for suspected trisomy 21, 18
or 13, two for possible mosaics, an additional 12 because of
other NIPT ﬁndings and one after a failed result. In addition,
invasive testing was done in 21 women with a normal NIPT
result, mostly indicated by ultrasound anomalies. Of those, ﬁve
showed an abnormal karyotype: the already described missed
trisomy 21 isochromosome, a triploidy, a small (0.1Mb) 9p
deletion, a 1.7Mb deletion on Xp and one mosaic trisomy 8.
A precise estimation of the reduction of the overall number
of invasive procedures attributable to the availability of NIPT
in the TRIDENT study is hampered by several factors. NIPT
performed by foreign commercial laboratories has been
available to Dutch women in neighboring countries, paid
out-of-pocket, since 2012. Of the 202 women who in the study
period received a high-risk result from the FCT and declined
NIPT, some may have chosen to have their blood sample
analyzed in a foreign laboratory. Numbers and outcome data
are unavailable to us.
What we do know, however, is that in The Netherlands
consistently around 50% of women with an increased FCT risk
result elect to undergo invasive testing.8,11 In our study, 1413
women undergoing FCT received a risk ≥1:200. Theoretically,
had NIPT not been available, 50% or 706 of them would have
opted for invasive testing. Adding the 21 who had invasive
testing because of ultrasound abnormalities results in a total
of 727 invasive tests. The actual number of invasive tests in
our study group was 53 plus 21 is 74, plus an unknown part
of the 202 women who declined our NIPT. The most
conservative calculation, if all 202 women would have chosen
invasive testing, results in a reduction from 727 to 276, or 62%.
DISCUSSION
Our ﬁrst evaluation of the TRIDENT study conﬁrms the
expected high accuracy of NIPT in a real-world setting. The
uptake of NIPT in this high-risk cohort was 86%. This led to a
major reduction in the number of invasive diagnostic
procedures, at the expense of one trisomy missed. No
unexpected live birth of a child with a trisomy occurred in this
cohort. No pregnancies were terminated after abnormal NIPT
without conﬁrmation in chorionic villi or amniotic ﬂuid cells.
Detection rates (DR) for the common trisomies (96% for
trisomy 21, 100% for trisomies 13 and 18) and false positive
rates (0.14% for trisomies 21 and 13, 0.07% for trisomy 18) were
comparable to previous studies.12 Our data support
introduction of NIPT as a safe second-tier screening test to
accurately select the small proportion of women truly at high
risk for fetal trisomy, and to reliably reassure all others.
The uptake of NIPT of 86% was similar to the hypothetical
interest of 82% in a previous questionnaire study,13 and the
88% found in a UK survey.14 Smaller prospective studies in
the US have reported uptakes of NIPT by women at elevated
risk ranging from 43 to 69%.3,15,16 However, data are difﬁcult
to interpret and compare because of ample opportunities to
obtain NIPT as a ﬁrst-tier screening test across the border.
Also, costs and reimbursement policies, and the extent of
invasive testing, are likely to have a considerable impact on
choices. The latter may vary from QF-PCR testing for
chromosomes 21, 18, 13, X and Y only, to traditional
karyotyping or high-resolution microarray. Preferences may
Table 4 Test characteristics of NIPT for fetal trisomy 21
Trisomy 21 Non-trisomy 21 Total
NIPT high risk T21 29 2 31
NIPT low risk T21 1 1354 1355
30 1356 1386
Sensitivity 29/30 = 96.7%.
Speciﬁcity 1354/1356 = 99.9%.
Positive predictive value 29/31 = 93.5%.
Negative predictive value 1354/1355 = 99.9%.
Table 5 Test characteristics of NIPT for fetal trisomy 18
Trisomy 18 Non-trisomy 18 Total
NIPT high risk T18 4 1 5
NIPT low risk T18 0 1381 1381
4 1382 1386
Sensitivity 4/4 = 100%.
Speciﬁcity 1381/1382 = 99.9%.
Positive predictive value 4/5 = 80.0%.
Negative predictive value 1381/1381 = 100%.
Table 6 Test characteristics of NIPT for fetal trisomy 13
Trisomy 13 Non-trisomy 13 Total
NIPT high risk T13 4 2 6
NIPT low risk T13 0 1380 1380
4 1382 1386
Sensitivity 4/4 = 100%.
Speciﬁcity 1380/1382 = 99.9%.
Positive predictive value 4/6 = 66.7%.
Negative predictive value 1380/1380 = 100%.
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change again when more extended cfDNA testing becomes
available.
The true clinical value of our study is that it conﬁrms the
expected major reduction in the number of invasive
procedures, which was the primary goal of NIPT
development.17 It is well known that for biological reasons
NIPT will never be as accurate as the analysis of fetal cells
taken from amniotic ﬂuid.18 However, according to our data,
there appears to be only a small price to pay for trading some
accuracy for safety. The single fetal trisomy missed by NIPT
was detected at routine prenatal ultrasound. The underlying
isochromosome was absent in the cytotrophoblast, which is
the source of the cfDNA tested by NIPT. Although rare, false
negative trisomy 21 cases have been reported.19,20 Adequate
counseling should ensure that women understand the high
but not 100% accuracy of NIPT.
Although there is still controversy on the magnitude of the
fetal loss rate caused by invasive testing, the reduction of
invasive test procedures is certainly perceived as better care
both by health care providers and pregnant women. Moreover,
costs of invasive testing, a sum of laboratory work and
procedure by maternal–fetal medicine specialists, are higher
than the cost of NIPT, and this gap is rapidly widening. Health
economic consequences of our study will be subject of
reviewing.21 Others found similar reductions in invasive testing
after introduction of NIPT.1,22–24 A recent decision-analysis
modeling study concluded that offering NIPT to the high-risk
population would reduce the number of invasive procedures
by 72%, and NIPT for the general population a reduction of
60%.25 An important consequence is the rapidly declining
experience of clinicians in performing invasive procedures.1,26
Quality assurance and training programs need to be adapted,
and more centralized care seems unavoidable.
In the Netherlands, only University Genetic Laboratories are
licensed to do genetic testing. Some of these laboratories
already had several years of experience in fetal cfDNA analysis
while others started this service especially for the TRIDENT
study.27–29 Although the numbers are still limited, we found
no evidence for an inferior performance of NIPT by our
laboratories compared to other providers.9
A possible limitation of the method used in our study was
our inability to measure fetal fraction in all cases. Only recently
algorithms became available to calculate fetal fraction based
on the single read next generation sequencing (NGS) data that
we have used.30
Our choice for whole genome sequencing entailed that other
trisomies, as well as large duplications and deletions, also
became detectable. In such cases, decisions on informing and
advising couples were taken after multidisciplinary discussions
between lab specialists, clinical geneticists and maternal–fetal
medicine specialists. NIPT data on the occurrence of these
anomalies in a population with an increased risk based on
the FCT are slowly emerging.31,32 In our study, 31% of the
chromosomal abnormalities found were other than trisomy
21, 13 or 18. This is higher than the number calculated by
Norton et al.,33 which might be because of the fact that the
study populations were different because of different screening
protocols. Using our protocol, many of the non-detectable
anomalies as described by Norton et al.33 such as other
trisomies, unbalanced rearrangements and insertions/
deletions would have been detectable.
Biologically, NIPT resembles direct analysis of chorion villus
cytotrophoblasts, and additional ﬁndings are likely to be
comparable.18,27,34 As expected therefore, a number of cases
of conﬁned placental mosaicisms such as trisomy 7, 8 and 16
and one case of true fetal mosaicism leading to, respectively,
false positive and a false negative result were found. Our series
conﬁrmed the previously described association between a
mosaic placenta and fetal growth restriction.35,36 As with CVS,
advance knowledge of such a risk may be beneﬁcial to clinical
management. The need to perform invasive testing in these
cases, and if so either with CVS or AS, will be discussed
between laboratory specialists and clinicians on a case to case
base. The advice to the parents will depend on gestational age,
type of chromosome anomaly, presence or absence of
ultrasound ﬁndings and parental preferences.34,37 This is a
new area of research into possible additional clinical value of
NIPT beyond trisomy 21, 13 and 18. In our study, couples
had no option to reject information on secondary ﬁndings,
but a choice will be offered in our future studies as not all
couples may want this information.
The use of NIPT as a secondary screening test does not
diminish the false negative rate of the initial screening test
(FCT) but mainly lowers the false positive rate. As the DR of
NIPT for common aneuploidies is higher than the DR of FCT
(~80–95%),38–40 replacement of FCT by NIPT as a ﬁrst-tier test
will lower the false negative rate. We expect that the indication
for NIPT will broaden to a larger proportion of pregnant
women in the coming years, in line with international trends.
This will enable us to further invest in equipment and improve
workﬂow, leading to higher efﬁciency, lower cost per test and
faster TATs, an issue our pregnant women highly value. With
improving technology also, the scope of testing may become
wider. The overall impact of the introduction of NIPT into
our national screening program will therefore need continuous
monitoring with emphasis not only on technical performance
but also on patient preferences and outcome data of all
pregnancies.
In conclusion, the ﬁrst evaluation of our TRIDENT study with
full clinical follow-up conﬁrms the clinical usefulness of NIPT as
a safe and reliable alternative to invasive diagnostic testing for
high-risk pregnant women. Our trial license was granted for two
years and has been extended for another two years. We are
continuing to follow up all cases of NIPT; we will separately
publish questionnaire results on women’s evaluation after
receiving test-results (Van Schendel et al., in preparation) and
re-analyze the health economic consequences. With these
combined data, we will discuss with the government and all
involved stakeholders a plan of action for formal implementation
of NIPT in the Dutch national prenatal screening program.
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WHAT’S ALREADY KNOWN ABOUT THIS TOPIC?
• Non-invasive prenatal testing (NIPT) for trisomies 21, 18 and 13 is
mainly offered in a commercial setting.
• Offering NIPT to pregnant women at increased risk for fetal trisomy
leads to a reduction in invasive testing.
WHAT DOES THIS STUDY ADDS?
• NIPT implemented as a contingent test under the umbrella of a
national health authority-supported fetal trisomy screening program
facilitates optimal counseling with close to 100% follow-up, results
in 86% uptake and conﬁrms a major reduction of invasive tests.
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